Glypressin (Terlipressin Acetate)

Glypressin is an injectable solution that contains the synthetic vasopressin analogue terlipressin acetate. It is supplied in a sterile liquid form for intravenous administration and is marketed in the European Union as a prescription‑only medication. As a selective V1‑receptor agonist, Glypressin produces vasoconstriction of splanchnic vessels, which helps lower portal pressure and supports renal perfusion in specific liver‑related conditions and may be used under specialist supervision.

Glypressin is indicated for several acute complications associated with advanced liver disease and portal hypertension.

- Management of acute variceal bleeding in patients with cirrhosis. - Treatment of type 1 hepatorenal syndrome to improve renal function. - Control of severe portal hypertension when other measures are insufficient. - Adjunct therapy during endoscopic procedures to reduce bleeding risk. - Short‑term use in patients with refractory ascites where portal pressure reduction is required. - Bridge therapy for patients awaiting liver transplantation to stabilize hemodynamics.

The safety profile of Glypressin includes both frequently observed reactions that are generally mild and self‑limiting, as well as less common but potentially serious events that require prompt medical attention.

Common: - Transient abdominal discomfort or cramping, usually resolving without intervention. - Mild headache that may improve with standard analgesics. - Nausea or vomiting, often occurring shortly after infusion. - Flushing of the skin, particularly on the face and upper torso.

Serious: - Severe hypertension or hypertensive crisis, which may require immediate antihypertensive therapy. - Cardiac arrhythmias, including tachycardia or atrial fibrillation, that can be symptomatic. - Ischemic complications such as myocardial infarction, peripheral limb ischemia, or mesenteric ischemia. - Acute respiratory distress or pulmonary edema, presenting with shortness of breath and hypoxia.

When prescribing Glypressin, clinicians should evaluate patient history and monitor for conditions that could increase the risk of adverse outcomes.

- Known hypersensitivity to terlipressin acetate or any excipients; avoid use in such patients. - Uncontrolled hypertension; Glypressin may exacerbate blood pressure elevation. - Active coronary artery disease or recent myocardial infarction, due to vasoconstrictive effects. - Peripheral vascular disease, which can predispose to ischemia with V1 agonist therapy. - Pregnancy and lactation status is not well established; use only if potential benefit outweighs risk. - Concomitant use of other vasopressors or inotropes; may lead to additive cardiovascular effects.

Glypressin can interact with several drug classes, and awareness of these relationships helps prevent clinically significant effects.

Avoid: - Concurrent use of other potent vasoconstrictors (e.g., norepinephrine, phenylephrine) due to additive increase in vascular tone. - Strong CYP3A4 inhibitors, which may alter terlipressin metabolism and increase exposure.

Use with caution: - Diuretics, especially loop diuretics, as they may affect intravascular volume and renal response. - Beta‑blockers, because combined effects on blood pressure can be unpredictable. - Anticoagulants, since severe hypertension may raise bleeding risk despite the anti‑hemorrhagic indication. - Renin‑angiotensin system blockers (ACE inhibitors or ARBs) because they may blunt the desired hemodynamic response.